Keryx Biopharma (KERX) Announces Ferric Citrate Phase 3 Data in IDA, NDD-CKD: Primary Endpoint Met
Tweet Send to a Friend
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced presentation of additional data from its pivotal Phase 3 study for iron deficiency anemia ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
